physIQ announced Jason Luke has been appointed to the company’s Medical Advisory Board.
Canary Medical announced the appointment of Lisa Suennen as President, Digital and Data Solutions.
Emmes has expanded capabilities in India during the last two years and has seen surging growth in the region, with local revenue increasing by 400% and global study revenue increasing by more than 50%.
ACTO has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence by Everest Group.
eClinical Solutions announced its accreditation in Medidata’s Site Cloud: End of Study platform.
The Almac Group has pledged to be net zero by 2045.
Quanticate announced plans for further expansion and new jobs in Toronto in 2023 as it thrives post-pandemic after it opened the office in 2019.
physIQ announced that OncoBay Clinical, Inc., has joined its Intrepid Partner Program.
Elligo Health Research just won the Fast 50 Award, sponsored by the Austin Business Journal.
Jumo Health announced it has been recognized by Inc. Magazine in its inaugural Power Partner Awards.
AeroSafe Global announced that it earned the No. 1 spot on the 2022 Top 100 list of fast-growing, privately owned companies in the Rochester and Finger Lakes region.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.